Drug intelligence / Profile preview

MANA-512

Development stage: Preclinical
Lead developer: Mana Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

MANA-512 is an investigational immunotherapy developed by Mana Therapeutics targeting solid tumors. It is a preclinical T cell receptor (TCR) therapy specific for the WT1 (Wilms' tumor 1) antigen, designed to recognize and eliminate WT1-expressing cancer cells. WT1 is overexpressed in various solid tumors, making it a promising target for TCR-based treatments; preclinical studies have demonstrated a strong safety profile and immunological anti-tumor activity, validating MANA's tumor antigen selection approach.[8]

Targets

WT1-HLA-I (Wilms tumor 1-derived peptide presented by HLA class I)

Beyond the preview

Go deeper on MANA-512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MANA-512.

Explore the full profile